Center for Clinical Studies

Houston, Texas 77598

4 studies enrolling now · 76 studies all time

What they study most

Acne Vulgaris, Actinic Keratosis, Active Nonsegmental Vitiligo, Alopecia Areata, Arthritis, Psoriatic, Atopic, Atopic Dermatitis, Cardiovascular Disease, Cardiovascular Diseases, Chronic Plaque Psoriasis, Chronic Spontaneous Urticaria (CSU), Dermatitis

Studies at this site

• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo — Recruiting now
• Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients — Recruiting now
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Recruiting now
• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis — Running, not enrolling
• A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) — Stopped early
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis — Completed
• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 — Running, not enrolling
• A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients — Stopped early
• A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis — Completed
• A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp — Stopped early
• LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris — Completed
• LEO 90100 in the Treatment of Psoriasis Vulgaris — Completed
• Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis — Completed
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis — Completed
• A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa — Stopped early
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis — Completed
• A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis — Completed
• A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is — Stopped early
• Vascular Inflammation in Psoriasis - Apremilast — Completed
• Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis — Completed
• This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is — Completed
• Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO) — Status unconfirmed
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) — Completed
• Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients — Withdrawn before enrolling
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. — Completed
• A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis — Completed
• The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1% — Completed
• Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris — Completed
• Phase 3 Papulopustular Rosacea Study — Completed
• A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis — Completed
• PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis — Completed
• Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema — Completed